title: Acute nitric oxide synthase inhibition and endothelin-1-dependent arterial pressure elevation.
abstract: Key evidence that endogenous nitric oxide (NO) inhibits the continuous, endothelin (ET)-1-mediated drive to elevate arterial pressure includes demonstrations that ET-1 mediates a significant component of the pressure elevated by acute exposure to NO synthase (NOS) inhibitors. This review examines the characteristics of this pressure elevation in order to elucidate potential mechanisms associated with the negative regulation of ET-1 by NO and, thereby, provide potential insight into the vascular pathophysiology underlying NO dysregulation. We surmise that the magnitude of the ET-1-dependent component of the NOS inhibitor-elevated pressure is (1) independent of underlying arterial pressure and other pressor pathways activated by the NOS inhibitors and (2) dependent on relatively higher NOS inhibitor dose, release of stored and de novo synthesized ET-1, and ETA receptor-mediated increased vascular resistance. Major implications of these conclusions include: (1) the marked variation of the ET-1-dependent component, i.e., from 0 to 100% of the pressure elevation, reflects the NO-ET-1 regulatory pathway. Thus, NOS inhibitor-mediated, ET-1-dependent pressure elevation in vascular pathophysiologies is an indicator of the level of compromised/enhanced function of this pathway; (2) NO is a more potent inhibitor of ET-1-mediated elevated arterial pressure than other pressor pathways, due in part to inhibition of intravascular pressure-independent release of ET-1. Thus, the ET-1-dependent component of pressure elevation in vascular pathophysiologies associated with NO dysregulation is of greater magnitude at higher levels of compromised NO.
authors.affiliation: Research Service, Department of Pharmacology and Cell Biophysics, Veterans Affairs Medical Center, University of Cincinnati College of Medicine Cincinnati, OH, USA.
authors.forename: Robert M
authors.initials: RM
authors.lastname: Rapoport
keywords: acute; arterial blood pressure; endothelin converting enzyme inhibitor; endothelin receptor antagonist; endothelin-1; nitric oxide synthase inhibitor
references.citation: Circulation. 1995 Feb 1;91(3):771-5
references.pmid: 7828305
references.citation: J Hypertens. 2004 Jan;22(1):111-9
references.pmid: 15106802
references.citation: J Am Soc Nephrol. 1995 Nov;6(5):1476-81
references.pmid: 8589326
references.citation: Nat Med. 1995 Sep;1(9):894-901
references.pmid: 7585214
references.citation: Am J Physiol. 1991 Jul;261(1 Pt 2):R257-63
references.pmid: 1650147
references.citation: Am J Physiol Renal Physiol. 2001 Dec;281(6):F1132-40
references.pmid: 11704565
references.citation: J Hypertens. 1996 Aug;14(8):975-81
references.pmid: 8884552
references.citation: Am J Physiol. 1995 Aug;269(2 Pt 2):H743-8
references.pmid: 7653640
references.citation: Hypertension. 2000 Jan;35(1 Pt 2):518-23
references.pmid: 10642352
references.citation: Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H1080-9
references.pmid: 21685265
references.citation: Br J Pharmacol. 1996 May;118(2):352-4
references.pmid: 8735637
references.citation: J Cardiovasc Pharmacol. 1994 Jul;24(1):144-50
references.pmid: 7521479
references.citation: Hypertension. 1997 Jul;30(1 Pt 1):22-8
references.pmid: 9231816
references.citation: Am J Physiol Regul Integr Comp Physiol. 2011 Jun;300(6):R1288-95
references.pmid: 21368267
references.citation: Curr Pharm Des. 2010;16(37):4089-102
references.pmid: 21247398
references.citation: Eur J Anaesthesiol. 2007 Aug;24(8):689-96
references.pmid: 17437657
references.citation: J Appl Physiol (1985). 1997 May;82(5):1593-600
references.pmid: 9134909
references.citation: Circulation. 1992 May;85(5):1894-8
references.pmid: 1572045
references.citation: Nitric Oxide. 2001 Aug;5(4):370-6
references.pmid: 11485375
references.citation: Br J Pharmacol. 2012 Mar;165(6):1992-1999
references.pmid: 21951225
references.citation: Hypertension. 1997 Nov;30(5):1204-9
references.pmid: 9369277
references.citation: Hypertension. 1998 Nov;32(5):844-8
references.pmid: 9822442
references.citation: Stroke. 2013 Aug;44(8):2128-33
references.pmid: 23788583
references.citation: J Cardiovasc Pharmacol. 1998 Apr;31(4):618-22
references.pmid: 9554813
references.citation: Proc Natl Acad Sci U S A. 1988 Dec;85(24):9797-800
references.pmid: 3059352
references.citation: Am J Physiol Heart Circ Physiol. 2006 Nov;291(5):H2075-81
references.pmid: 16751289
references.citation: J Cardiovasc Pharmacol. 2001 Nov;38(5):784-95
references.pmid: 11602825
references.citation: Pharmacology. 1997 Dec;55(6):299-308
references.pmid: 9413859
references.citation: J Cardiovasc Pharmacol. 1994 May;23(5):765-71
references.pmid: 7521459
references.citation: J Cardiovasc Pharmacol. 2012 Nov;60(5):483-94
references.pmid: 22987051
references.citation: Peptides. 1998;19(2):211-23
references.pmid: 9493852
references.citation: Hypertension. 2003 Oct;42(4):831-6
references.pmid: 12925563
references.citation: Scand J Clin Lab Invest. 2013 Aug;73(5):436-43
references.pmid: 23777299
references.citation: Heart Fail Rev. 2001 Dec;6(4):265-76
references.pmid: 11447301
references.citation: Eur Respir J. 2003 Jan;21(1):19-24
references.pmid: 12570103
references.citation: Nitric Oxide. 2009 Nov-Dec;21(3-4):201-9
references.pmid: 19735735
references.citation: Am J Physiol. 1999 Aug;277(2):H524-32
references.pmid: 10444477
references.citation: Br J Pharmacol. 2013 Sep;170(2):266-77
references.pmid: 23713522
references.citation: J Pharm Pharmacol. 1998 Sep;50(9):1051-8
references.pmid: 9811167